The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor.
